Related Experiment Video

Updated: Mar 20, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.7K

Extended-release acetylsalicylic acid for secondary prevention of stroke and cardiovascular events

Kevin P Bliden1, Udaya S Tantry1, Rahul Chaudhary1

  • 1a Inova Center for Thrombosis Research and Drug Development , Inova Heart and Vascular Institute , Fairfax , VA , USA.

Expert Review of Cardiovascular Therapy
|May 25, 2016
PubMed

Insights

Extended-release aspirin may offer an alternative to standard aspirin for secondary prevention of cardiovascular events, potentially mitigating bleeding risks. Further research is needed to confirm its safety and efficacy compared to traditional aspirin therapy.

Area of Science:

  • Cardiology
  • Pharmacology
  • Neurology

Background:

  • Aspirin is a cornerstone in secondary prevention of cardiovascular and cerebrovascular events.
  • Standard aspirin therapy presents limitations including bleeding, gastrotoxicity, and short duration of effect.
  • Extended-release (ER) aspirin formulations aim to address these limitations.

Purpose of the Study:

  • To review the use of aspirin for secondary prevention of stroke and cardiovascular events.
  • To describe pharmacodynamics of standard and extended-release aspirin formulations.
  • To evaluate ER aspirin as a potential alternative to standard aspirin therapy.

Main Methods:

  • Comprehensive literature search of PubMed articles until May 2016.
  • Review of active- and placebo-controlled clinical trials.
  • Analysis of American and European recommendations and controversies.

Main Results:

  • Standard aspirin therapy increases bleeding risk with P2Y12 inhibitors or oral anticoagulants.
  • Ongoing trials are evaluating low-dose oral anticoagulants as aspirin alternatives.
  • ER aspirin may offer a safer alternative, but further studies are warranted.

Conclusions:

  • ER aspirin formulations may provide an alternative to standard aspirin for secondary cardiovascular prevention.
  • Further research is necessary to confirm the safety and efficacy of ER aspirin.
  • Addressing safety concerns associated with standard aspirin therapy is crucial.
Abstract

Keywords:
Antiplateletacetylsalicylic acidaspirincardiovascular diseaseplateletsecondary preventionthromboxane

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.7K
Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation06:04

Upper-extremity Approach for Secondary Access in Transfemoral Transcatheter Aortic Valve Implantation

Published on: August 8, 2025

683

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
429
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
391
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
569
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
407
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
103